Piper Jaffray analyst David Amsellem says his firm's survey of 29 orthopedic surgeons reinforces his confidence that Pacira Pharmaceuticals will be able to drive sustainable long-term volume growth for Exparel. Out of the 29 respondents, 83% noted that the data from the total knee arthroplasty study would result in them viewing Exparel's efficacy profile at least slightly more favorably, Amsellem tells investors in a research note. He believes Pacira is trading at an attractive risk/reward profile and reiterates an Overweight rating on the name with a $60 price target.